.png){kind=icon}
.png){kind=icon}
Return
A ROS-responsive nanoplatform for early MRI diagnosis and management of Alzheimer’s disease
.png){kind=icon}
OA
AI
Q
宋
L
Y
F
高
F
DOI：10.1016/j.apsb.2026.07.054.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Alzheimer’s disease (AD) presents significant challenges for early diagnosis and effective intervention largely due to the limitations in blood‒brain barrier (BBB) penetration and the complex, multifaceted pathogenesis. To tackle those challenges, this study proposes a reactive oxygen species (ROS)-responsive nanoplatform (termed CUTK), modified with receptor for advanced glycation end products (RAGE)-targeting KLVFFAEDC peptide on the surface, for the precise co-delivery of curcumin and ultrasmall superparamagnetic iron oxide nanoparticles (USPIO) across the pathological BBB. The incorporated thioketal (TK) linker ensures ROS-triggered, on-site co-release of the payloads for specific accumulation. CUTK demonstrated disease-targeted delivery, enhanced cellular uptake, reduced Aβ burden, alleviated neuroinflammation, and reprogrammed microglia. As an activatable T2 contrast agent, USPIO enabled sensitive magnetic resonance imaging (MRI) detection of early AD pathology by turning on exclusive MRI signals of lesions. Longitudinal multi-modal MRI and behavioral tests confirmed that CUTK treatment mitigated AD progression and facilitated cognitive recovery while restoring the AD brain microenvironment of APP/PS1 transgenic mice. Collectively, this novel smart nanoplatform CUTK offered an appealing paradigm for the early MRI diagnosis and management of AD.
Keywords:
Alzheimer’s disease
Magnetic resonance imaging
Early diagnosis
Targeted delivery
ROS-responsive
RAGE targeting
Quantitative susceptibility mapping
Theranostics
Journal
IF:
14.6
Papers:
2.6K
Citations:
2.1W
Organization
Cited Papers